Noa Krawczyk, PhD
NYU Langone Health, Division of Epidemiology, Center for Opioid Epidemiology and Policy, Department of Population Health - Assistant Professor
Email: noa.krawczyk@nyulangone.org
Education
PhD, Mental Health, Johns Hopkins Bloomberg School of Public HealthBA, Biology, Hunter College at the City University of New York – Macaulay Honors College
Research Interests
Substance use, Opioids, Overdose, Health services, Mental health, Criminal justice, Treatment BIO
Noa Krawczyk is an Assistant Professor in the Department of Population Health at NYU School of Medicine and a member of the Center for Opioid Epidemiology and Policy. She completed her PhD in the Department of Mental Health at the Johns Hopkins Bloomberg School of Public Health, where she studied substance use epidemiology, and previously worked as a Fulbright research scholar to study treatment and health services among cocaine users in Brazil. Her research focuses on studying ways to address barriers to evidence-based treatment for opioid use disorders and improving quality and effectiveness of care, especially among vulnerable groups such as persons with criminal justice involvement. Her work centers on bridging research and practice by collaborating with health organizations, public health and government agencies and advancing science that can help inform evidence-based policies and practices that reduce harm and promote long term recovery. Projects
Principal Investigator, Beyond Treatment Initiation: Enhancing Opioid Use Disorder Care Transitions Across Health System Touchpoints. Active
Principal Investigator, Simulating the Impact of Office-Based Methadone Prescribing and Pharmacy Dispensing on OUD Treatment and Overdose in New York State: An Agent-Based Modeling Approach. Active
Principal Investigator, Trends in Psychosis Related to Hospitalizations Among Youth Following Cannabis Legalization in Colorado. Completed
Publications
Recent
Desai IK, Burke K, Li Y, Ganetsky V, Sugarman OK, Krawczyk N, Feder KA (2025).
Use of harm reduction practices by state-licensed specialty substance use treatment programs
Journal of Substance Use and Addiction Treatment, 174, 209711. doi: 10.1016/j.josat.2025.209711.
Use of harm reduction practices by state-licensed specialty substance use treatment programs
Journal of Substance Use and Addiction Treatment, 174, 209711. doi: 10.1016/j.josat.2025.209711.
Miller M, Wheeler-Martin K, Bunting AM, Cerda M, Krawczyk N (2025).
Changes in synthetic opioid-involved youth overdose deaths in the United States: 2018-2022
Pediatrics, 155 (6), e2024069488. doi: 10.1542/peds.2024-069488.
Changes in synthetic opioid-involved youth overdose deaths in the United States: 2018-2022
Pediatrics, 155 (6), e2024069488. doi: 10.1542/peds.2024-069488.
Borquez I, Williams AR, Hu MC, Scott M, Stewart MT, Harpel L, Aydinoglo N, Cerda M, Rotrosen J, Nunes EV, Krawczyk N (2025).
State sequence analysis of daily methadone dispensing trajectories among individuals at United States opioid treatment programs before and following COVID-19 onset
Addiction, 120 (6), 1207-1222. doi: 10.1111/add.70008. PMCID: PMC12048216.
State sequence analysis of daily methadone dispensing trajectories among individuals at United States opioid treatment programs before and following COVID-19 onset
Addiction, 120 (6), 1207-1222. doi: 10.1111/add.70008. PMCID: PMC12048216.
Ganetsky VS, Feder KA, Burke KN, Desai IK, Harris SJ, Krawczyk N (2025).
Integration of harm reduction principles and practices within specialty substance use treatment programs in New Jersey: A qualitative study of program leadership
Journal of Substance Use and Addiction Treatment, 174, 209703. doi: 10.1016/j.josat.2025.209703.
Integration of harm reduction principles and practices within specialty substance use treatment programs in New Jersey: A qualitative study of program leadership
Journal of Substance Use and Addiction Treatment, 174, 209703. doi: 10.1016/j.josat.2025.209703.
Allen B, Krawczyk N, Basaraba C, Jent VA, Yedinak JL, Goedel WC, Krieger M, Pratty C, Macmadu A, Samuels EA, Marshall BDL, Neill DB, Cerda M (2025).
Investigating heterogeneous effects of an expanded methadone access policy with opioid treatment program retention: A Rhode Island population-based retrospective cohort study
American Journal of Epidemiology [Epub 2025 May 1]. doi: 10.1093/aje/kwaf092.
Investigating heterogeneous effects of an expanded methadone access policy with opioid treatment program retention: A Rhode Island population-based retrospective cohort study
American Journal of Epidemiology [Epub 2025 May 1]. doi: 10.1093/aje/kwaf092.
Notable
Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: Addressing a critical care gap
Journal of Substance Abuse Treatment, 103, 1-8. doi: 10.1016/j.jsat.2019.05.002. PMCID: PMC6612429.
Krawczyk N, Picher CE, Feder KA, Saloner B (2017).
Only one in twenty justice-referred adults in specialty treatment for opioid use receive methadone or buprenorphine
Health Affairs, 36 (12), 2046-2053. doi: 10.1377/hlthaff.2017.0890. PMCID: PMC6035729.
Dr. Krawczyk's MyBibliography Profile
Selected Press